Fractyl Health 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- REMAIN-1 met its 6-month co-primary endpoint with high statistical significance (p-value of 0.0023) in 308 participants who had lost an average of 18.3% of body weight on tirzepatide before stopping treatment.
- Rovita participants retained about 80% of the weight they had lost on tirzepatide, and the separation from sham widened from month 1 through month 6.
- At 6 months, 1 in 3 Rovita participants were weight stable or had lost more weight, nearly half retained at least 80% of their weight loss, and more than 97% maintained clinically meaningful weight loss at 1 year in a post hoc analysis.
- In a post hoc analysis, treatment effects improved with longer ablation lengths; patients receiving 20 centimeters or more had less than half the weight regain of sham, with no associated safety signal reported.
- There were no device- or procedure-related serious adverse events, deaths, or unanticipated adverse device effects reported in the overall safety update; related events were mostly mild and generally occurred on the day of the procedure.
- Third-quarter 2026 R&D expenses were $12.5 million, compared with $17.5 million in the same period in 2025, and SG&A expenses were $6.2 million, compared with $5.2 million.
- Third-quarter 2026 net loss was $14.2 million, compared with $45.6 million in the same period in 2025, and adjusted EBITDA was negative $16 million, compared with negative $20.8 million in the 3rd quarter of 2025.
- Cash and cash equivalents were $31.5 million as of September 30th, 2026; cash used in operations was just below $16 million in the 3rd quarter.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon, and welcome to the Fractyl Health Third Quarter 2026 Financial Results and Business Update Call. As a reminder, this conference call is being recorded. At this time, all participants are in a listen-only mode. There will be a question-and-answer session following management's prepared remarks. I will now turn the call over to Brian Luque, Head of Investor Relations and Corporate Development at Fractyl. Brian, you may begin. Thank you.
This afternoon, we issued a press release that outlines the topics we plan to discuss today. This release is available at www.fractyl.com under the Investors tab. Joining us on the call today are Dr. Harith Rajagopalan, Chief Executive Officer, and Lara Smith Weber, Chief Financial Officer. Before we begin, one change to our format. For the first time, we invited all of our shareholders to submit and vote on questions for management through Say by Robinhood. After our prepared remarks, I will read a selection of the most voted shareholder questions, and then the operator will open the line to our covering analysts. Thank you to everyone who took part. During this call, we make forward-looking statements, which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements.
We provide a comprehensive list of risk factors in our SEC filings, including the quarterly report on Form 10-Q filed today, which I encourage you to review. Any forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements, even if subsequent events cause the company's views to change. It is now my pleasure to pass the call over to Harith.
Thank you, Brian. Good afternoon, everyone. Nearly 30 million Americans are now on GLP-1 therapy. Approximately 1 million are discontinuing GLP-1s each month. Yet, those who take GLP-1s, only one in 12 Americans remain on them for obesity at the end of three years. What happens for the 11 out of 12 who stop? On average, 85% of patients regain weight, and roughly two-thirds of the weight comes back within a year. That is a systemic pattern driven by biology, not an individual failure of willpower, and it doesn't have to be this way. Why does the weight come back? We believe the answer is in the gut. Modern unhealthy diets accelerate cellular aging in the gut. In plain terms, those changes make us more prone to obesity, and the aging gut may retain a metabolic memory that perpetuates disease.
GLP-1 medicines have proven that dramatic weight loss is possible, but they neither reverse the underlying cellular aging causing obesity nor regenerate a healthy gut. They leave the underlying problem untouched. Revita aims to do both. It is designed to reset the gut's metabolic memory as a one-time outpatient procedure designed to ablate the damaged, unhealthy lining of the duodenum to allow healthier tissue to regenerate in its place. LASIK for obesity. It means the gut is now working with, not against, a patient's weight loss program. This means the potential for better overall health and weight loss that can actually last even after the drugs are stopped. Last month, we put that idea through the most rigorous stress test we could conceive, REMAIN-1, in which patients were driven to achieve rapid and profound weight loss and then stopped high-dose tirzepatide outright.
It's the most extreme example of what could happen in the real world, and the study met its six-month co-primary endpoint with high statistical significance. Today, I want to take you through three things. Number one, what the REMAIN-1 top line showed, why we believe it is clinically meaningful, and what to expect next as we look to complete the study in Q1 2027. Number two, why the market is ready for Revita. Number three, how we have rebuilt Fractyl around it. Then Lara will take you through the quarter. I will close on three milestones in front of us: submitting our De Novo marketing application later this quarter, 12-month co-primary and key secondary endpoints in the first quarter of 2027, and clarity on the CMS RAPID reimbursement rule. All value-accretive milestones funded with the cash we have on hand. Let me take each in turn.
What did REMAIN-1 top line show? We designed REMAIN-1 to provide a rapid and clean assessment of Revita safety and efficacy in the post-GLP-1 weight maintenance setting. Adults with obesity who had never taken a GLP-1 started tirzepatide, stayed on it until they had lost at least 15% of their body weight. On average, they lost 18.3% over about 25 weeks, and about half reached the maximum 15 milligram dose. The drug was stopped, and participants were randomized two to one to Revita or to a sham procedure, double-blind. 308 participants make up the modified intention-to-treat population. The study met its six-month co-primary endpoint with high statistical significance, P-value of 0.0023.
Revita participants kept about 80% of the weight they had lost on the tirzepatide, and whichever way we analyze it across primary and every pre-specified sensitivity analysis, the result was highly statistically significant with two to three zeros in the P-value. If anything, we believe the comparison with sham is conservative. Sham participants were about three times as likely as Revita participants to restart an anti-obesity medication, which potentially masks the true effect of Revita. Two findings I want you to remember. First, the effect grew over time. The gap between Revita and sham widened at every visit from month one to three to six, and nearly doubled between months three and six. In our pilot, Revita patients leveled off at about 80% of their weight loss retained at one year, and so far, the pivotal is tracking that experience. Second, what this means for an individual patient.
One in three Revita participants were weight stable or had lost more weight six months after stopping tirzepatide. Nearly half kept at least 80% of their weight loss. When we apply the method for our 12-month responder endpoint at six months as a post-hoc analysis, more than 97% of Revita participants maintained clinically meaningful weight loss at one year against a performance goal of greater than 50%. The formal test of that second co-primary endpoint will come with our 12-month data in the first quarter of 2027. We also continue to see a dose response with ablation length. In our pilot, the benefit was clearest above 14 centimeters. With a much larger study, we now have the numbers and granularity to see it more precisely.
In a post-hoc analysis, separation from sham begins at a dose as low as 12 centimeters and progressively better with a longer ablation for the full length of the duodenum, or roughly 20 centimeters. Our best performing patients received a full treatment of 20 centimeters or more, and they achieved less than half the regain of sham. REMAIN-1 contributes not only the evidence to support our planned De Novo submission later this quarter, but also the evidence to inform how to train physicians to perform the procedure after approval for maximum effect. Each additional 2 centimeters takes about two minutes, and physicians lengthen their ablations as they gained experience in the study. With the six-month and 12-month data, we will have adequate information to define the appropriate treatment length for real-world implementation. There is an added benefit to the dose response we are observing.
Given the novelty of the duodenum as a target, dose response builds credibility in target validation, something we are hearing from physicians over and over again. On safety, the profile was what we have come to expect from Revita. There were no device or procedure-related serious adverse events, no deaths, no unanticipated adverse device effects. Related events were mostly mild, and the vast majority of them occurred only on the day of the procedure. The next clinical milestone for REMAIN-1 is clear. In the first quarter of 2027, we expect top-line 12-month data from the second co-primary endpoint. If both co-primary endpoints are met, our key secondary endpoints, including complete ablation and higher run-in weight loss, will then be formally tested in sequence. Here is what success looks like at 12 months. First, we meet the second co-primary endpoint, which is the pre-specified performance goal.
Based on what we see at six months, we are highly confident in that result. Second, at longer ablation lengths, we want to see even greater effects as we showed at six months. We hope to see the Revita arm with a complete treatment maintain a majority of its weight loss at one year. The physicians we have been talking to and our patient market research tells us that a full ablation should be the expected standard procedure for Revita if it is authorized. Now let us step out of the data and into the doctor's office. In a consumer market, physicians will not talk to patients about placebo-adjusted differences. They will say, "Here is what you can expect to keep." REMAIN-1 top line clearly demonstrated that patients have the potential to retain the majority of their hard-won weight loss with a low risk of serious side effects.
Now let's turn to why the market is ready for Revita. At our commercial strategy day in September, we laid out why we see Revita's launch as market activation, not market creation. Our commercial model is a targeted and efficient launch at bariatric and metabolic centers of excellence. The patients, the interventional physicians and surgeons, the procedure rooms, and the payer precedent already exist. What is missing is a durable off-ramp. Each year, roughly 4 million Americans stop a GLP-1 after losing at least 15% of their body weight and fall within the BMI range we studied. That is the population that REMAIN-1 enrolled. Those patients are concentrated in ASMBS centers of excellence that we can name. There are about 1,000 accredited bariatric centers in the U.S.
Our launch plan focuses on the top 100 to 200 of them, many of them sites that we already know from our clinical program. Each of those centers already sees more than 2,000 GLP-1 patients a year, and we model 250 to 500 Revita procedures per center per year at maturity, well within each center's capacity. The metabolic interventionalist physicians in those centers already have the skills and the enthusiasm for procedures like Revita. In REMAIN-1, a half day of training and about four proctored cases brought them to proficiency. That, backed by a capital-efficient center of excellence model, is why we believe a commercial team of tens of people, not hundreds, can support a launch. In 2025, before our pivotal data, we commissioned third-party market research across roughly 750 patients, prescribers, and hospital stakeholders. Three findings stand out from that market research.
First, patients understand the risks of discontinuation very well. Nearly eight in 10 patients were both already aware of and very concerned about regaining weight after stopping a GLP-1. Over 80% ranked a one-time procedure that lets them stop their GLP-1 without regaining weight as among the features that mattered most to them. The patients most interested were those who are currently on a GLP-1. Amazingly, despite the very well-known benefits of long-term GLP-1 treatment, one in three surveyed GLP-1 users would prefer to stop taking their GLP-1 and undergo a hypothetical endoscopic procedure than continue staying on their drug. Prescribers told us the evidence that moves them most is what happens to the patients in the Revita arm, which is exactly how REMAIN-1 reads out. Second, patients want to make this decision with their doctor, and that is good news for Revita.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
9 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
